Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.
about
Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Combination immuno-oncology th ...... vasion for precision medicine.
@en
Combination immuno-oncology th ...... vasion for precision medicine.
@nl
type
label
Combination immuno-oncology th ...... vasion for precision medicine.
@en
Combination immuno-oncology th ...... vasion for precision medicine.
@nl
prefLabel
Combination immuno-oncology th ...... vasion for precision medicine.
@en
Combination immuno-oncology th ...... vasion for precision medicine.
@nl
P2860
P356
P1476
Combination immuno-oncology th ...... vasion for precision medicine.
@en
P2093
Masaru Katoh
P2860
P304
P356
10.21037/JTD.2018.03.62
P577
2018-03-01T00:00:00Z